Late Major Hemoptysis After Lung Volume Reduction With Coils Induced by Dual Antiaggregation Therapy

Ann Thorac Surg. 2016 Feb;101(2):e49-50. doi: 10.1016/j.athoracsur.2015.06.045.

Abstract

Lung-volume reduction using coils is an effective and safe treatment for selected patients presenting severe emphysema and hyperinflation. Most complications occur during the first 30 days after the procedure. Although frequent, hemoptysis is usually transient and minor. Antiaggregation therapy is common in patients with emphysema who, very often, have additional tobacco-associated comorbidities. Aspirin is considered safe for most major interventions; however, clopidogrel is mainly contraindicated and considered an exclusion criterion. We present a case of life-threatening hemoptysis caused by dual antiaggregation therapy "accidentally" introduced 3 months after the procedure. So far no recommendations exist on the optimal therapeutic strategy after lung-volume reduction with coils.

Publication types

  • Case Reports

MeSH terms

  • Aspirin / adverse effects*
  • Clopidogrel
  • Hemoptysis / chemically induced*
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / adverse effects*
  • Pneumonectomy / instrumentation*
  • Postoperative Complications / chemically induced*
  • Pulmonary Emphysema / surgery
  • Severity of Illness Index
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Time Factors

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin